Search Results

Jumpcode Genomics and Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., announced the companies have settled their patent dispute and have partnered to bring together their combined foundational IP in the field of targeted depletion of undesired transcripts such as ribosomal RNAs from NGS libraries using CRISPR-based technology.

Takara Bio USA, Inc. announced that it has once again prevailed in its second patent dispute with Jumpcode Genomics, Inc.

Jumpcode Genomics today announced the results of a new study demonstrating the potential of Jumpcode Genomics depletion technology for improving future large-scale infectious disease testing and pandemic response.

Jumpcode Genomics, a genome technology platform company focused on improving the understanding of human biology, announced a partnership with 10x Genomics to integrate the Jumpcode Single Cell RNA Boost Kit with the 10x Genomics Chromium Single Cell Gene Expression platform.

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, today announced a collaboration and co-marketing partnership with Jumpcode Genomics that validates Jumpcode’s CRISPRclean technology on Element’s AVITI System.

AI-Powered Genomic Mapping Could Revolutionize Treatment of Rare Genetic Diseases